These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17786634)

  • 21. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.
    Sai Y; Dai R; Yang TJ; Krausz KW; Gonzalez FJ; Gelboin HV; Shou M
    Xenobiotica; 2000 Apr; 30(4):327-43. PubMed ID: 10821163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450.
    Bojić M; Sedgeman CA; Nagy LD; Guengerich FP
    Eur J Pharm Sci; 2015 Jun; 73():49-56. PubMed ID: 25840124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 isoenzymes--importance for the internist.
    Kerremans AL
    Neth J Med; 1996 Jun; 48(6):237-43. PubMed ID: 8710046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P450 enzymes: novel options for cancer therapeutics.
    McFadyen MC; Melvin WT; Murray GI
    Mol Cancer Ther; 2004 Mar; 3(3):363-71. PubMed ID: 15026557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
    Baston E; Leroux FR
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship for human cytochrome P450 substrates and inhibitors.
    Lewis DF; Modi S; Dickins M
    Drug Metab Rev; 2002; 34(1-2):69-82. PubMed ID: 11996013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Astrocytic cytochromes p450: an enzyme subfamily critical for brain metabolism and neuroprotection].
    Malaplate-Armand C; Leininger-Muller B; Batt AM
    Rev Neurol (Paris); 2004 Jul; 160(6-7):651-8. PubMed ID: 15247853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochromes P450 and metabolism of xenobiotics.
    Anzenbacher P; Anzenbacherová E
    Cell Mol Life Sci; 2001 May; 58(5-6):737-47. PubMed ID: 11437235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochromes p450: roles in diseases.
    Pikuleva IA; Waterman MR
    J Biol Chem; 2013 Jun; 288(24):17091-8. PubMed ID: 23632021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.
    Lewis DF
    Biochem Pharmacol; 2000 Aug; 60(3):293-306. PubMed ID: 10856424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450s and cholesterol homeostasis.
    Pikuleva IA
    Pharmacol Ther; 2006 Dec; 112(3):761-73. PubMed ID: 16872679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P450 inhibitors of use in medical treatment: focus on mechanisms of action.
    Vanden Bossche H; Koymans L; Moereels H
    Pharmacol Ther; 1995; 67(1):79-100. PubMed ID: 7494862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective inhibitors of cytochromes P450.
    Halpert JR; Guengerich FP; Bend JR; Correia MA
    Toxicol Appl Pharmacol; 1994 Apr; 125(2):163-75. PubMed ID: 8171425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.
    Chun J; Kent UM; Moss RM; Sayre LM; Hollenberg PF
    Drug Metab Dispos; 2000 Aug; 28(8):905-11. PubMed ID: 10901699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WhichCyp: prediction of cytochromes P450 inhibition.
    Rostkowski M; Spjuth O; Rydberg P
    Bioinformatics; 2013 Aug; 29(16):2051-2. PubMed ID: 23740742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
    Downie D; McFadyen MC; Rooney PH; Cruickshank ME; Parkin DE; Miller ID; Telfer C; Melvin WT; Murray GI
    Clin Cancer Res; 2005 Oct; 11(20):7369-75. PubMed ID: 16243809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marked inhibition of hepatic cytochrome P450 activity in cholesterol-induced atherosclerosis in rabbits.
    Irizar A; Ioannides C
    Toxicology; 1998 Apr; 126(3):179-93. PubMed ID: 9674966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design.
    Poulos TL
    Pharm Res; 1988 Feb; 5(2):67-75. PubMed ID: 3073382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of cytochrome P450 in tumour development and progression and its potential in therapy.
    Murray GI
    J Pathol; 2000 Dec; 192(4):419-26. PubMed ID: 11113857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals.
    Usmani KA; Cho TM; Rose RL; Hodgson E
    Drug Metab Dispos; 2006 Sep; 34(9):1606-14. PubMed ID: 16790556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.